Braver Wealth Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q4
Sell
-302,712
Closed -$14.9M 86
2015
Q3
$14.9M Buy
302,712
+86,151
+40% +$4.94M 3.71% 8
2015
Q2
$12.6M Sell
216,561
-5,781
-3% -$338K 3.07% 9
2015
Q1
$12.8M Sell
222,342
-22,608
-9% -$1.24M 2.62% 12
2014
Q4
$12.4M Buy
+244,950
New +$11.9M 2.53% 11
2014
Q3
Sell
-144,153
Closed -$6.49M 79
2014
Q2
$6.49M Sell
144,153
-8,061
-5% -$347K 1.68% 13
2014
Q1
$6.43M Buy
+152,214
New +$6.38M 1.84% 14

Other funds holding IHE

Braver Wealth Management's IHE Position: Q4 2015 in Review

Braver Wealth Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q4 2015, closing a stake of 302,712 shares — an estimated $14.9M sold.

Braver Wealth Management first reported a position in IHE in Q1 2014 and held it in 6 quarters. The position peaked at $14.9M in Q3 2015. 103 funds tracked by Wall St. Rank hold IHE as of Q4 2015.

  • Braver Wealth Management reported no remaining iShares US Pharmaceuticals ETF position as of Q4 2015 after selling out during the quarter.
  • Braver Wealth Management sold 302,712 iShares US Pharmaceuticals ETF shares in Q4 2015, an estimated $14.9M.
  • Braver Wealth Management first reported a position in iShares US Pharmaceuticals ETF in Q1 2014 and held it in 6 quarters.
  • Braver Wealth Management's iShares US Pharmaceuticals ETF position peaked at $14.9M in Q3 2015.
  • 103 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2015.

Based on Braver Wealth Management's 13F filing for Q4 2015, filed 11 Feb 2016.